Missouri And Other States Face Potentially Costly Dilemma Over Treating Inmates With Hepatitis C | KCUR

Missouri And Other States Face Potentially Costly Dilemma Over Treating Inmates With Hepatitis C

Dec 13, 2017

In a corner of her house in Sparta in southwest Missouri, Jymie Jimerson has set up a kind of shrine. It has Native American art representing her Cherokee heritage alongside Willie Nelson albums, books and photos in remembrance of her late husband. On one side is a copy of Willie’s mid-’70s LP, “Red Headed Stranger.”

“When Steve was young, he had red hair and a red beard, so he always really identified with Willie’s Red Headed Stranger,” Jimerson says. “I try to keep it up there as a reminder of better days.”

Steve Jimerson, who died in January 2017, was sentenced to life in prison for his role in the shooting deaths of two men in 1995.
Credit Missouri Department of Corrections

Steve Jimerson was sentenced to life in prison in 1996 for his role in the shooting deaths of two men. Jymie says her husband’s life had been ravaged by drug abuse, but after he entered prison, he got sober and become a mentor for other inmates.

“Once he got inside, recovery became his life,” Jymie says. “And that was his passion until the day he died.”

Steve Jimerson died at age 59 on January 6, 2017 due to complications from hepatitis C, a liver infection that’s especially widespread among prison inmates but, in recent years, rarely treated in prison.

According to the Centers for Disease Control and Prevention, the most common way inmates get hepatitis C is by sharing equipment used for injecting drugs, tattooing and piercing with other people who are already infected.

Civil liberties groups in Missouri and at least seven other states are now suing to get more inmates treated with new-generation hepatitis C drugs that are highly effective but also very costly.

Steve Jimerson's death certificate showing he died of liver failure attributable to Hepatitis C.

After Steve Jimerson was diagnosed with hepatitis C while in prison, Jymie says he closely watched for news of treatment developments.

In 2013, Gilead Sciences introduced Sovaldi, the first of a new generation of drugs called direct-acting antivirals that can cure hepatitis C in many cases with minimal side effects. But the excitement was dampened by the drug’s price. A full course of treatment cost $84,000.

Jymie says that her husband was not given direct-acting antivirals, and internal state data obtained by the MacArthur Justice Center in St. Louis shows he was not  alone.

In 2016, around 5,000 Missouri inmates had hepatitis C. The data show that no more than 14 received the drugs.

By the fall of last year, Jimerson’s health was deteriorating rapidly, and he grew pessimistic about the prospects for a cure.

“He told me that if someone had to die to get the DOC [Department of Corrections] to change their policy, he was O.K. with it being him,” Jymie says.

As recently as 2012, scores of Missouri inmates were being treated with an old hepatitis C drug called Interferon, which was often ineffective and notorious for its debilitating side effects.  

But in 2013, the Federal Bureau of Prisons started changing treatment guidelines to replace the old hepatitis C drugs with new ones.

Those guidelines are followed by many states, including Missouri, according to a spokesperson from Corizon Health, the private company that provides health care for Missouri’s inmates.

Missouri phased out the old drugs, but it hasn’t used the new drugs nearly as often. That has left only a handful of inmates getting any hepatitis C drug treatment at all.

Earlier this year, the American Civil Liberties Union and MacArthur Justice Center sued to get the Missouri Department of Corrections to provide direct-acting antiviral drugs to inmates with hepatitis C who  qualify for treatment.

ACLU lawyer Tony Rothert says the state’s current treatment practices violate the Constitution’s Cruel and Unusual Punishments Clause.

“The Supreme Court has said that in the context of medical care, that means that prisons cannot be deliberately indifferent to serious medical needs,” Rothert says. “Hepatitis C fairly easily satisfies this test, because if left untreated, there's a fair chance that you will die.”

Advocates making this argument recently got a big boost for their case. Just weeks ago, a federal judge in Florida ordered that state’s prisons to start providing direct-acting drugs to its inmates.

“It was a great victory for people who are incarcerated and have Hepatitis C because now we have a federal judge who said, ‘Look, this is just unconscionable,’ and the state is going to have to do something about it,” says Elizabeth Paukstis, public policy director of the National Viral Hepatitis Roundtable.

In July, the Missouri lawsuit took a leap forward when the judge overseeing the case certified it as a class action on behalf of state inmates with hepatitis C. The Missouri Department of Corrections and Corizon, which are defendants in the lawsuit, have appealed that ruling.

Both the Missouri Department of Corrections and Corizon declined to comment on the suit or their hepatitis C treatment protocols.

But Gregg Gonsalves, an assistant professor of epidemiology at the Yale School of Public Health, says that if Missouri and other states are required to offer the new drugs, they would face a huge problem.

“Even if they wanted to treat patients, they would break the bank. They would run out of money to treat every other medical condition,” Gonsalves says.

For example, if Missouri gave the 2,500 inmates that the ACLU says are candidates for Harvoni, the acting antiviral drug it now uses, the cost would exceed $236 million, based on its list price.

That far exceeds the Department of Corrections’ entire budget for inmate health. 

Gonsalves says the emergence of newer, cheaper drugs could help, and some state prison systems have managed to negotiate discounts.

Even at a lower cost, though, providing these drugs on a large scale could still cost states a fortune. But advocates insist it’s worth it to stop the disease from spreading. 

“The impetus for treating infectious disease in the prison system is that it’s a population you can reach, it’s a population you can cure, and it’s a population you can help prevent onward infections from,” Gonsalves says.

Jymie Jamerson understands that many people might be skeptical about providing expensive health care for prison inmates. But she hopes they can see them as more than people convicted of crimes.

“I’m not condoning what they did. I’m not condoning criminals,” she says. “What I’m saying is they’re human beings. And there are hundreds, hundreds of first-time offenders that this medication would cure them. So that when they went home, they could actually spend time and enjoy a little bit of life with their families.”

Alex Smith is a health reporter for KCUR. You can reach him on Twitter @AlexSmithKCUR